Logo

Paired Ends: Michael Glynn

Aug 14, 2012
Premium

Michael Glynn has resigned as Pacific Biosciences' chief commercial officer. Glynn joined PacBio in October 2011 from Genzyme, where he served as regional president of Japan-Asia Pacific and senior vice president. He also held various roles at Boston Scientific and was CEO of Codman Group, a developer of healthcare decision support software and home telemedicine systems. He holds an MBA from Macquarie University in Sydney and a BS from the National University of Ireland.

Filed under

Clinical Sequencing
Sequencing
Next-Generation Sequencing
Pacific Biosciences
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.